Delivery Order SPE2DB22D3016-SPE2DB25FBHB8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,431.13 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract represents a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $370,595.28 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,037.49 delivery order on September 2, 2025, for Zepbound 10 mg/0.5 ml pen (semaglutide injection), with performance completion scheduled for September 3, 2025. The contract is structured as a firm fixed price delivery order under a non-competitive set-aside designation, with performance to be executed at the contractor's Conshohocken, Pennsylvania location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $16,675.15 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price contract, which was not set-aside, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on July 22, 2025, with a ceiling value of $34,194.89. This firm fixed price delivery order, which completes on July 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The award was made through open competition with no set-aside designation, and performance is based at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,558.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,143.89 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. The contract, which represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is scheduled for completion by August 18, 2025. This delivery order was competitively awarded without...
- The Defense Logistics Agency awarded a delivery order valued at $14,645.91 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on September 9, 2025, with completion targeted for September 10, 2025. This competitive award utilizes firm fixed pricing with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $13,120.39 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $8,787.92 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pens on May 12, 2025, with completion expected by May 13, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor vehicle running through December 2026. The place of performance is...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBHB8Delivery Order
The Defense Logistics Agency awarded a $13,958.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on September 3, 2025, with completion expected by September 4, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no set-aside designation and involves firm fixed pricing for pharmaceutical supply. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. This order is part of AmerisourceBergen's comprehensive pharmaceutical support vehicle with the DLA, which enables the company to supply a wide range of medications, vaccines, and medical supplies to military healthcare programs globally. The company's federal contract portfolio demonstrates extensive experience delivering specialty medications and brand-name drugs across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The delivery of Zepbound, a GLP-1 receptor agonist medication used for weight management, reflects the expanding scope of pharmaceutical commodities provided through the DLA's medical supply chain to support federal health programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.0k | 9/3/25 |